Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
14 févr. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon Pharmaceuticals, Aquestive Therapeutics, Takeda, Ovid Therapeutics, Eisai, Biohaven Pharmaceuticals, UCB Pharma
08 févr. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon Pharmaceuticals, Aquestive...
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
08 févr. 2024 08h00 HE
|
Neurona Therapeutics
$120M financing will support advancement of ground-breaking regenerative cell therapies for chronic CNS disorders
Epilepsy Therapeutics market is projected to grow at a CAGR of 8.1% by 2034: Visiongain
02 févr. 2024 04h00 HE
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Epilepsy Therapeutics Market Report 2024-2034: Forecasts by Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), by...
APAC Epilepsy Therapeutic Market Poised for Growth, Set to Expand by USD 449.35 Mn through 2023-2028
31 janv. 2024 11h13 HE
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Epilepsy Therapeutic Market in APAC 2024-2028" report has been added to ResearchAndMarkets.com's offering. The epilepsy therapeutic market in the...
Urgent call for timely, affordable access to new life-changing epilepsy treatments in Canada
10 janv. 2024 07h00 HE
|
Canadian Epilepsy Alliance
Calgary, AB, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The Canadian Epilepsy Alliance, along with physicians, patients and their families are calling on provincial Health Ministers to address an unmet need...
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
08 janv. 2024 08h00 HE
|
Praxis Precision Medicines, Inc.
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion...
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
04 janv. 2024 16h49 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public...
Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis
04 janv. 2024 12h00 HE
|
CROSSJECT
Communiqué de presse Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis Crossject élargit ses activités d'accès au marché dans le cadre des...
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
04 janv. 2024 12h00 HE
|
CROSSJECT
Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® Crossject expanding market access activities in preparation for filing for marketing authorization ...